



FOR IMMEDIATE RELEASE

Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

News Summary:

- New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsⁱ.
- Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted analyte interactions to increase resolution and sensitivity while reducing peak tailing for metal-sensitive analytes.
- Next-generation system delivers a new level of simplicity and instrument intelligence to biologics QC analyses, helping laboratories meet quality, compliance, and on-time product delivery goals.

Milford, MA, USA and Munich, Germany – Analytica 2024 – April 9, 2024 – Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of failed runs and out-of-specification results.

The bio-inert design of the instrument features Waters MaxPeak HPS Technology applied to key internal components including the system flow path to reduce unwanted interactions from metal-adsorbing analytes. The system pairs with [Waters QuanRecovery™ Vials and Plates](#), as well as [MaxPeak Premier HPLC Columns with eConnect™ Column Tag Technology](#), allowing for more confident platform methods that eliminate the need for lengthy column conditioning and method development.

“Many of the challenges that impact productivity and revenues for QC labs come from human error. We collaboratively developed the Alliance iS Bio HPLC System with our customers to address daily routine challenges and help meet more stringent and evolving compliance requirements while working to achieve shorter product release timelines,” said Fraser McLeod, Vice President, General Manager, QA/QC, Waters Corporation. “We built every feature of this powerful HPLC platform, including the use of bio-inert surface technology at key sample touchpoints, with simplicity, sophistication and efficiency in mind, to help biopharma QC labs save time and money.”

The Alliance iS Bio HPLC System also combines with Waters compliance-ready [Empower Chromatography Software](#) to help laboratories collect, manage, and report chromatography test results. It integrates seamlessly with Waters and third-party liquid chromatography instruments to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.

The Alliance iS Bio HPLC System is now available globally.

Additional Resources

- Learn more about the [Alliance iS Bio HPLC System](#) on Waters.com
- View the [Waters Analytica 2024 Online Press Kit](#)
- View the [Alliance iS Bio HPLC System Virtual Launch Webinar](#)
- Waters App Note: “[Deploying the Alliance iS Bio HPLC System as a Modern HPLC for Biopharmaceutical Analysis in QC Environments](#)”
- Waters App Note: “[Modernizing Compendial SEC Methods for Biotherapeutics Using the Alliance iS Bio HPLC System](#)”
- Follow and connect with Waters via [LinkedIn](#), [Twitter](#), and [Facebook](#)

About Waters Corporation (www.waters.com)

(NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,900 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Waters, MaxPeak, Alliance, QuanRecovery and eConnect are trademarks of Waters Technologies Corporation.

#

Contact:

Kevin Kempfskie
Senior Director of Public Relations
Waters Corporation
kevin_kempfskie@waters.com
+1.617.413.4333

ⁱ Estimate based on Waters market research in 2022 after surveying 56 global pharmaceutical company QC labs.